SCHEMBL19994487

SCHEMBL19994487

CCOC(=O)c1ccc2[nH]c(-c3ccc(N(C)C)cc3)nc2c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 10/20 0.83
SIRT1 Q96EB6 8/20 0.83
SIRT3 Q9NTG7 2/20 0.62
PKN1 Q16512 1/20 0.60
PKN2 Q16513 1/20 0.60
PARP1 P09874 1/20 0.49
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 2/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
TCF4 P15884 1/20 0.47
CTNNB1 P35222 1/20 0.47
RHEB Q15382 1/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30343739 1.00 SIRT2 (0.83) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL20001715 0.86 SIRT2 (0.65) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL18668553 0.86 SIRT2 (0.83) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL17275543 0.86 PKN1 (0.65) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL465519 0.84 SIRT2 (0.62) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL1663678 0.83 SIRT2 (0.58) SIRT2SIRT1PARP1ALDH1A1NPC1
SCHEMBL15223904 0.83 SIRT2 (0.58) SIRT2SIRT1PARP1ALDH1A1NPC1
SCHEMBL20001676 0.82 CHEK2 (0.64) SIRT2SIRT1PKN1PKN2PARP1
SCHEMBL20001644 0.82 SIRT2 (0.57) SIRT2SIRT1PARP1ALDH1A1NPC1
SCHEMBL6178276 0.81 KDM4E (0.59) SIRT2SIRT1SIRT3PKN1PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2025-12-30 US disclosed
EP-3515904-B1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2024-01-17 EP disclosed
CN-110234640-B Benzimidazole derivatives as anticancer agents 利昂贝拉尔中心 2023-04-07 CN disclosed
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents CENTRE LEON BERARD (FR) 2022-11-03 US disclosed
US-11384081-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2022-07-12 US disclosed
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2021-09-23 US disclosed
EP-3515904-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS Centre Leon Berard (FR) 2019-07-31 EP disclosed
WO-2018054989-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CCAR2, MAPKAP1, BCOR SIRT2 1935/4885SIRT1 2148/4885SIRT3 1770/4885
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS TMBIM6, BAX, MAPK14 SIRT2 1954/4885SIRT1 2241/4885SIRT3 1988/4885
US-11384081-B2 Benzoimidazole derivatives as anticancer agents TMBIM6, BAX, MAPK14 SIRT2 1954/4885SIRT1 2241/4885SIRT3 1988/4885
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents TMBIM6, BAX, BCL2 SIRT2 1990/4885SIRT1 2253/4885SIRT3 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.